You Are Cordially Invited to
The Vascular Society of New Jersey
42st Annual Scientific Meeting
March 4, 2020
APA Hotel Woodbridge
120 S. Wood Avenue
Iselin, New Jersey
11:00-12:15 PM Lunch, Registration & Exhibition
12:15-12:30 PM Introduction and Business Meeting
Michael Ombrellino, MD
Keynote Address - "Contemporary Management of Complex Abdominal Aortic Aneurysms"
Virendra I. Patel, MD, MPH
Chief of Vascular Surgery, New York Presbyterian/Columbia University Medical Center
"Treatment of Submassive Pulmonary Embolism"
"The Role of Transfermoral Carotid Stenting in the Era of Transcarotid Artery Revascularization"
"The 5+2 Vascular Surgery Fellowship"
Break/Visit with Exhibitors
12th Annual Robert W. Hobson, II, MD Competition
Presentation of Hobson Award
Closing Remarks and Adjournment
Please join us after the close of the program for a cocktail reception and networking hour.
Vascular surgeons, nurses, and technicians.
Atlantic Health System designates this live educational activity for a maximum of 3.25 AMA PRA Category 1 CreditsÔ. Physicians should claim credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements of the Medical Society of New Jersey through the joint providership of Atlantic Health System and the Vascular Society of New Jersey. Atlantic Health System designates this live educational activity for a maximum of 3.25 AMA PRA Category 1 CreditsÔ. Physicians should claim credit commensurate with the extent of their participation in the activity. Atlantic Health System is accredited by the Medical Society of New Jersey to provide continuing medical education for physicians.
It is the policy of Atlantic Health System to ensure balance, independence, objectivity, and scientific rigor in all sponsored educational programs. All participating are expected to disclose to the program audiences any associated or apparent conflict(s) of interest related to the content of their presentation(s). Also disclosed will be any expected discussions of non-FDA-approved products or devices.